Are there any dietary restrictions while taking sofosbuvir and velpatasvir (Epclusa)?

Sofosbuvir and velpatasvir (Epclusa) combination is a prescription medicine used to treat hepatitis C in adults and children 3 years of age and older. The sofosbuvir-velpatasvir combination was approved in 2016 and is the first drug to treat all six hepatitis C genotypes. It can be used in people with or without cirrhosis (scarring of the liver). The sofosbuvir and velpatasvir combination is used to treat patients who have never been treated for hepatitis C before or who have tried other hepatitis C drugs that did not work for them.

The sofosbuvir-velpatasvir combination has two active drugsvelpatasvir and sofosbuvir. It comes in oral tablets and oral pills that you swallow or sprinkle on food, and studies showsofosbuvir and velpatasvir combination are effective in treating hepatitis C virus. In clinical trials, 89% to 99% of people who received the combination of sofosbuvir and velpatasvir achieved a sustained virologic response (SVR). Reaching SVR means the virus is no longer detectable in your body. This means that hepatitis C infection is considered curable. Cure rates vary depending on an individual's HCV genotype (the strain of virus they have) and medical history.

The original drug of sofosbuvir and velpatasvir has been launched in China and has entered the scope of Class B medical insurance. The domestic trade name is protonsa, and the specification (400mg+100mg)*28 tablets is priced at about 4,000 yuan per box. The original drug of sofosbuvir and velpatasvir has also been launched overseas. There are also generic drugs of sofosbuvir and velpatasvir produced in other countries. The price of the specification (400mg + 100mg) * 28 tablets produced by Everest Pharmaceutical Factory in Bangladesh is about 850 yuan per box (the price may fluctuate due to the exchange rate). The generic drugs produced abroad are basically the same as the original drugs at home and abroad.